Actinium Pharmaceuticals, Astellas collaborate on AWE platform technology

This article was originally published here

Actinium Pharmaceuticals has entered into a research and option agreement with Astellas Pharma to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) platform technology.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply